Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

The anticancer properties of iron core–gold shell nanoparticles in colorectal cancer cells

Authors Wu YN, Wu PC, Yang LX, Ratinac KR, Thordarson P, Jahn KA, Chen DH, Shieh DB, Braet F

Received 7 May 2013

Accepted for publication 21 June 2013

Published 2 September 2013 Volume 2013:8(1) Pages 3321—3331

DOI https://doi.org/10.2147/IJN.S47742

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Ya-Na Wu,1 Ping-Ching Wu,1 Li-Xing Yang,1 Kyle R Ratinac,2 Pall Thordarson,4 Kristina A Jahn,2 Dong-Hwang Chen,3 Dar-Bin Shieh,1,5,6 Filip Braet2,7

1Institute of Oral Medicine and Department of Stomatology, National Cheng Kung University Hospital, College of Medicine, Tainan, Taiwan; 2Australian Centre for Microscopy and Microanalysis, University of Sydney, Sydney, NSW, Australia; 3Department of Chemical Engineering, National Cheng Kung University, Tainan, Taiwan; 4School of Chemistry, University of New South Wales, Sydney, NSW, Australia; 5Center for Micro/Nano Science and Technology, National Cheng Kung University, Tainan, Taiwan; 6Advanced Optoelectronic Technology Center, National Cheng Kung University, Tainan, Taiwan; 7School of Medical Sciences (Discipline of Anatomy and Histology), The Bosch Institute, University of Sydney, Sydney, NSW, Australia

Abstract: Previously, iron core–gold shell nanoparticles (Fe@Au) have been shown to possess cancer-preferential cytotoxicity in oral and colorectal cancer (CRC) cells. However, CRC cell lines are less sensitive to Fe@Au treatment when compared with oral cancer cell lines. In this research, Fe@Au are found to decrease the cell viability of CRC cell lines, including Caco-2, HT-29, and SW480, through growth inhibition rather than the induction of cell death. The cytotoxicity induced by Fe@Au in CRC cells uses different subcellular pathways to the mitochondria-mediated autophagy found in Fe@Au-treated oral cancer cells, OECM1. Interestingly, the Caco-2 cell line shows a similar response to OECM1 cells and is thus more sensitive to Fe@Au treatment than the other CRC cell lines studied. We have investigated the underlying cell resistance mechanisms of Fe@Au-treated CRC cells. The resistance of CRC cells to Fe@Au does not result from the total amount of Fe@Au internalized. Instead, the different amounts of Fe and Au internalized appear to determine the different response to treatment with Fe-only nanoparticles in Fe@Au-resistant CRC cells compared with the Fe@Au-sensitive OECM1 cells. The only moderately cytotoxic effect of Fe@Au nanoparticles on CRC cells, when compared to the highly sensitive OECM1 cells, appears to arise from the CRC cells' relative insensitivity to Fe, as is demonstrated by our Fe-only treatments. This is a surprising outcome, given that Fe has thus far been considered to be the "active" component of Fe@Au nanoparticles. Instead, we have found that the Au coatings, previously considered only as a passivating coating to protect the Fe cores from oxidation, significantly enhance the cytotoxicity of Fe@Au in certain CRC cells. Therefore, we conclude that both the Fe and Au in these core–shell nanoparticles are essential for the anticancer properties observed in CRC cells.

Keywords: cancer therapy, Fe, gold-coated iron, nanoparticles, differential cytotoxicity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Optimal delivery of male breast cancer follow-up care: improving outcomes

Ferzoco RM, Ruddy KJ

Breast Cancer: Targets and Therapy 2015, 7:371-379

Published Date: 23 November 2015

Advances in cancer pain from bone metastasis

Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY

Drug Design, Development and Therapy 2015, 9:4239-4245

Published Date: 18 August 2015

Clinical epidemiology of epithelial ovarian cancer in the UK

Doufekas K, Olaitan A

International Journal of Women's Health 2014, 6:537-545

Published Date: 23 May 2014

Oncolytic viral therapy for pancreatic cancer: current research and future directions

Ady JW, Heffner J, Klein E, Fong Y

Oncolytic Virotherapy 2014, 3:35-46

Published Date: 17 February 2014

Update of research on the role of EZH2 in cancer progression

Shen L, Cui J, Liang S, Pang Y, Liu P

OncoTargets and Therapy 2013, 6:321-324

Published Date: 4 April 2013

Capecitabine in the management of colorectal cancer

Hirsch BR, Zafar SY

Cancer Management and Research 2011, 3:79-89

Published Date: 24 March 2011